Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens

Charles L. Murphy, Manfred Eulitz, Rudi Hrncic, Knut Sletten, Per Westermark, Teresa Williams, Sallie D. Macy, Craig Wooliver, Jonathan Wall, Deborah T. Weiss, Alan Solomon

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

The human amyloidoses represent a heterogeneous group of disorders characterized by the deposition of fibrillar protein in vital organs. Given the fact that at least 20 different molecules can form fibrils, the unambiguous identification of the type of amyloid deposited is critical to the correct diagnosis and treatment of patients with these disorders. Heretofore, this information has been inferred from particular clinical features of the disease, ancillary laboratory tests, and results of immunohistochemical analyses. However, to establish unequivocally the kind of protein that is deposited as amyloid, it is necessary to determine its chemical composition through amino acid sequencing or mass spectroscopy of material extracted from fibrillar deposits. We have developed a micromethod whereby such studies can be performed readily using sections of formalin-fixed, paraffin-embedded biopsy specimens. The ability to identify precisely the nature of the tissue deposits has diagnostic, therapeutic, and prognostic implications for patients with amyloid-associated disorders.

Original languageEnglish (US)
Pages (from-to)135-142
Number of pages8
JournalAmerican Journal of Clinical Pathology
Volume116
Issue number1
DOIs
StatePublished - Jul 1 2001

Fingerprint

Amyloidogenic Proteins
Amyloid
Paraffin
Formaldehyde
Biopsy
Protein Sequence Analysis
Amyloidosis
Mass Spectrometry
Proteins
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens. / Murphy, Charles L.; Eulitz, Manfred; Hrncic, Rudi; Sletten, Knut; Westermark, Per; Williams, Teresa; Macy, Sallie D.; Wooliver, Craig; Wall, Jonathan; Weiss, Deborah T.; Solomon, Alan.

In: American Journal of Clinical Pathology, Vol. 116, No. 1, 01.07.2001, p. 135-142.

Research output: Contribution to journalArticle

Murphy, CL, Eulitz, M, Hrncic, R, Sletten, K, Westermark, P, Williams, T, Macy, SD, Wooliver, C, Wall, J, Weiss, DT & Solomon, A 2001, 'Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens', American Journal of Clinical Pathology, vol. 116, no. 1, pp. 135-142. https://doi.org/10.1309/TWBM-8L4E-VK22-FRH5
Murphy, Charles L. ; Eulitz, Manfred ; Hrncic, Rudi ; Sletten, Knut ; Westermark, Per ; Williams, Teresa ; Macy, Sallie D. ; Wooliver, Craig ; Wall, Jonathan ; Weiss, Deborah T. ; Solomon, Alan. / Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens. In: American Journal of Clinical Pathology. 2001 ; Vol. 116, No. 1. pp. 135-142.
@article{0ab70bfb61ea4bf088b3c2a7c8e0c775,
title = "Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens",
abstract = "The human amyloidoses represent a heterogeneous group of disorders characterized by the deposition of fibrillar protein in vital organs. Given the fact that at least 20 different molecules can form fibrils, the unambiguous identification of the type of amyloid deposited is critical to the correct diagnosis and treatment of patients with these disorders. Heretofore, this information has been inferred from particular clinical features of the disease, ancillary laboratory tests, and results of immunohistochemical analyses. However, to establish unequivocally the kind of protein that is deposited as amyloid, it is necessary to determine its chemical composition through amino acid sequencing or mass spectroscopy of material extracted from fibrillar deposits. We have developed a micromethod whereby such studies can be performed readily using sections of formalin-fixed, paraffin-embedded biopsy specimens. The ability to identify precisely the nature of the tissue deposits has diagnostic, therapeutic, and prognostic implications for patients with amyloid-associated disorders.",
author = "Murphy, {Charles L.} and Manfred Eulitz and Rudi Hrncic and Knut Sletten and Per Westermark and Teresa Williams and Macy, {Sallie D.} and Craig Wooliver and Jonathan Wall and Weiss, {Deborah T.} and Alan Solomon",
year = "2001",
month = "7",
day = "1",
doi = "10.1309/TWBM-8L4E-VK22-FRH5",
language = "English (US)",
volume = "116",
pages = "135--142",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "1",

}

TY - JOUR

T1 - Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens

AU - Murphy, Charles L.

AU - Eulitz, Manfred

AU - Hrncic, Rudi

AU - Sletten, Knut

AU - Westermark, Per

AU - Williams, Teresa

AU - Macy, Sallie D.

AU - Wooliver, Craig

AU - Wall, Jonathan

AU - Weiss, Deborah T.

AU - Solomon, Alan

PY - 2001/7/1

Y1 - 2001/7/1

N2 - The human amyloidoses represent a heterogeneous group of disorders characterized by the deposition of fibrillar protein in vital organs. Given the fact that at least 20 different molecules can form fibrils, the unambiguous identification of the type of amyloid deposited is critical to the correct diagnosis and treatment of patients with these disorders. Heretofore, this information has been inferred from particular clinical features of the disease, ancillary laboratory tests, and results of immunohistochemical analyses. However, to establish unequivocally the kind of protein that is deposited as amyloid, it is necessary to determine its chemical composition through amino acid sequencing or mass spectroscopy of material extracted from fibrillar deposits. We have developed a micromethod whereby such studies can be performed readily using sections of formalin-fixed, paraffin-embedded biopsy specimens. The ability to identify precisely the nature of the tissue deposits has diagnostic, therapeutic, and prognostic implications for patients with amyloid-associated disorders.

AB - The human amyloidoses represent a heterogeneous group of disorders characterized by the deposition of fibrillar protein in vital organs. Given the fact that at least 20 different molecules can form fibrils, the unambiguous identification of the type of amyloid deposited is critical to the correct diagnosis and treatment of patients with these disorders. Heretofore, this information has been inferred from particular clinical features of the disease, ancillary laboratory tests, and results of immunohistochemical analyses. However, to establish unequivocally the kind of protein that is deposited as amyloid, it is necessary to determine its chemical composition through amino acid sequencing or mass spectroscopy of material extracted from fibrillar deposits. We have developed a micromethod whereby such studies can be performed readily using sections of formalin-fixed, paraffin-embedded biopsy specimens. The ability to identify precisely the nature of the tissue deposits has diagnostic, therapeutic, and prognostic implications for patients with amyloid-associated disorders.

UR - http://www.scopus.com/inward/record.url?scp=17844409327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844409327&partnerID=8YFLogxK

U2 - 10.1309/TWBM-8L4E-VK22-FRH5

DO - 10.1309/TWBM-8L4E-VK22-FRH5

M3 - Article

VL - 116

SP - 135

EP - 142

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 1

ER -